Friday, September 30, 2022


Biotechnology News Magazine

Richard Laxer Appointed a Non-Executive Director of Oxford Science

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

Richard Laxer is a veteran of GE Capital, serving the company for 34 years before retiring in 2018 as CEO and Chairman.

Richard Laxer held a number of senior executive roles at GE Capital across the US, Asia and Europe, leading global teams to develop and execute financing strategies that were critical to the success of a broad range of multi-billion-dollar world-leading businesses.

Since leaving GE Capital, Richard has used his experience and expertise to advise companies which are using cutting-edge and innovative technologies to disrupt the financial services industry. Richard has served as a senior advisor to Warburg Pincus and is currently a non-executive director to three of its portfolio companies: Vodeno Technology, Aion and Singular Bank.

“I am delighted to welcome Rich to the Board of Oxford Science Enterprises,” said Chris Chambers, Chairman of the Board. “He has had a hugely successful career in the global financial services industry, where he has an exceptional record of growing and transforming a diverse portfolio of businesses, including start-ups. His financial expertise and extensive networks are a complementary addition to the Board, and I look forward to working with him to leverage his leadership and operational experience to support our portfolio of high potential technology and life science companies that are poised to make a positive change to the world.”

“I am thrilled to be joining the Board of Oxford Science Enterprises,” said Richard Laxer. “The pioneering science and technology advancing from the University of Oxford has significant potential to address some of the major global impact challenges that we face today. I am excited to support the company in its investments and to champion these new ventures into disruptive new enterprises.”

Richard has proven experience navigating complex market conditions, managing enterprise risk alongside restructuring and integrating large businesses to deliver on financial targets. His extensive expertise of financing strategies includes, private equity, debt, corporate and commercial finance will be invaluable in directing Oxford Science Enterprises’ global ambition of transforming world-leading science into a high value portfolio of world-changing businesses.

Richard joined GE Capital in 1984 after gaining a Bachelor’s degree in Business, with a minor in Economics, from Skidmore College, Saratoga Springs, New York, US.


Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine